


REMARKS/ARGUMENTS

By the present amendment, applicants have canceled Claims 4, 9-11, 14, 16-17, and 19-20. In addition, applicants have amended Claims 3, 5-8, 12-13, 15, 18, 21-23, 25-27, and 29 to correct either multiple dependencies or dependency. No new matter has been added. Therefore the claims remaining for consideration by the Examiner are Claims 1-3, 5-8, 12-13, 15, 18, and 21-29.

Additionally, applicants have amended the specification to insert a claim of priority and place the Abstract on a separate sheet. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7945



John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Date: January 7, 2005